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Purpose: Smoking affects arterial stiffness, thus causing an elevation in central blood   pressure 
(CBP). The present study was designed to examine whether smoking cessation treatment 
improved CBP and arterial stiffness.
Patients and methods: We conducted an observational study of 70 patients receiving   smoking 
cessation treatment. Before and 60 weeks after the start of a 12-week varenicline treatment, 
we measured brachial blood pressure, CBP, brachial-ankle pulse wave velocity (baPWV), 
normalized radial augmentation index (rAIx@75), left ventricular weight, and left ventricular 
diastolic function of each patient. The data were compared between the patients who succeeded 
in quitting smoking (smoking cessation group; n = 37) and those who failed to quit smoking 
(smoking group; n = 33).
Results: Baseline characteristics were similar in both groups. Brachial blood pressure remained 
unchanged in both groups. CBP, baPWV , and rAIx@75 decreased significantly in the smoking 
cessation group, while these parameters showed no significant change in the smoking group. Thus, 
CBP, baPWV , and rAIx@75 showed greater decrease in the smoking cessation group than in the 
smoking group (CBP, −7.1 ± 1.4 mmHg vs 1.2 ± 2.7 mmHg; P , 0.01; baPWV , −204 ± 64 cm/s 
vs −43 ± 72 cm/s; P , 0.01; rAIx@75, −6.4 ± 2.8% vs −1.0 ± 3.9%; P , 0.01). Left   ventricular 
weight and left ventricular diastolic function remained unchanged in both groups.
Conclusion: Patients in the smoking cessation group showed significant improvement in CBP, 
baPWV , and rAIx@75. These results indicate that smoking cessation can improve arterial stiff-
ness and CBP.
Keywords: central blood pressure, augmentation index, brachial-ankle pulse wave velocity, 
smoking cessation, varenicline
Introduction
Smoking induces a temporary elevation in blood pressure. The elevation in blood 
  pressure induced by smoking one cigarette lasts for a period of 15 minutes or more.1 
Blood pressure may remain elevated in heavy smokers. Habitual smokers show 
  elevation in blood pressure during daytime activities,2 or they show an elevation in 
central blood pressure (CBP).3 CBP induces a more direct mechanical stress on the 
left ventricle, large arteries, and vital organ vasculature than does brachial blood 
pressure. The impact of CBP has been reported in large-scale intervention trials and 
population-based studies, such as the CAFÉ–ASCOT study4 and the SHS study.5 In 
addition, smoking might cause masked hypertension.6 However, a detailed evalua-
tion of the influence of chronic smoking on blood pressure has not been performed 
thus far.7 The relationship between smoking cessation and arterial wall thickness and Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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stiffness has been reported by van den Berkmortel et al.8 CBP 
can now be measured noninvasively, and CBP measurement 
using such methods has yielded many new findings. It is 
well known that elevation in CBP, rather than elevation in 
brachial blood pressure, is more closely associated with the 
onset of cardiovascular events.9 The impact of smoking ces-
sation with nicotine replacement on arterial stiffness remains 
unknown. In recent years, drug therapy with varenicline, an 
α4β2 nicotinic acetylcholine receptor partial agonist, has 
been actively used in helping smokers to quit smoking.10,11 
The present study was undertaken to evaluate the influence 
of smoking cessation with varenicline on CBP.
Methods
Patients and study design
We conducted an observational study for 1 year on 70 patients 
receiving smoking cessation treatment at our clinic.   Brachial 
blood pressure, CBP, radial augmentation index (AI), 
brachial-ankle pulse wave velocity (baPWV), left ventricular 
weight, and left ventricular diastolic function were measured 
before and 60 weeks after the start of the smoking cessation 
treatment. Varenicline, which was administered for 12 weeks 
(0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, 
and then 1.0 mg twice daily for a total of 12 weeks), was used 
for smoking cessation. The carbon monoxide (CO) level in 
expired gas was measured at 2-week intervals using a piCO 
Smokerlyzer (Bedfont, Kent, UK) to check whether the 
patients had quit smoking. Of the 70 patients, 56 completed 
the 12-week treatment. Of these 56 patients, 19 resumed 
smoking during the treatment period. During the 1-year 
observational study after the end of smoking cessation, 
data were analyzed by dividing the patients into a smoking 
  cessation group (37 patients who quit smoking until 1 year 
after the end of treatment) and a smoking group (33 patients 
who resumed smoking).
All patients were informed about the study procedure. 
Written informed consent was obtained from all patients 
participating in the study. The study protocol was approved 
by the Institutional Ethics Committee.
Brachial blood pressure, CBP, and radial AI were measured 
by radial tonometry by using HEM9000-AI (Omron Health-
care, Kyoto, Japan). Because the radial AI is affected by meals, 
it was measured on an empty stomach. To account for the influ-
ence of  heart rate (HR), radial AI was corrected for HR (75/m) 
and expressed as rAIx@75. The baPWV was determined from 
the pulse waveforms recorded from both forearms and both 
ankles using the formula PWV (Omron Healthcare, Kyoto, 
Japan). Left ventricular weight and left ventricular diastolic 
  function were measured by echocardiography (VIVID™ S6; 
GE Healthcare, Milwaukee, WI). Left ventricular weight was 
determined from the M-mode ultrasound image by using the 
equation of Devereux.12 Left ventricular mass index (LVMI) 
was calculated by dividing the left ventricular weight by body 
surface area of the patient. Left ventricular diastolic function 
was evaluated by measuring mitral annulus velocity (e′) at 
early diastole by tissue Doppler imaging.
Measurement of cBP and rAix@75
The pulse pressure waveform of the radial artery was 
recorded using an automated tonometry system (HEM-
9000AI; Omron Healthcare, Kyoto, Japan) with the patient in 
a sitting position after resting for $5 minutes. The waveform 
was automatically calibrated using the built-in oscillometric 
brachial sphygmomanometer, and the peak and trough of 
the radial pressure wave were adjusted to brachial systolic 
blood pressure (SBP) and diastolic blood pressure (DBP), 
respectively. The second peak (late systolic inflection) was 
automatically detected by an algorithm programmed into the 
HEM-9000AI system using the second maxima of the fourth 
derivative of the radial pressure waveform to determine the 
radial AI as well as the late or second SBP (SBP2). This 
algorithm is described in more detail elsewhere.13 The height 
of the second peak corresponds to the SBP2 value obtained 
using HEM-9000AI. The value of SBP2 is very similar to 
that of aortic CBP recorded using invasive techniques,14 and 
thus, SBP2 was used as an estimate of CBP. CBP determined 
using HEM9000-AI was comparable to that determined using 
a generalized aorta–radial transfer function.15,16 The AI was 
calculated using the following formula: (SBP2 − DBP)/
(the first peak SBP − DBP) × 100. Because AI is influenced by 
the HR, AI was normalized for a HR of 75 bpm (rAIx@75), 
as proposed by Wilkinson et al.17 In this study, these measure-
ments were performed by a single expert investigator.
Measurement of baPWV
The baPWV was also used to assess arterial stiffness. 
Measurement of baPWV was performed as described 
  previously.18 Briefly, baPWV was determined from the pulse 
waveforms recorded from both forearms and both ankles 
using the formula PWV (Omron Healthcare, Kyoto, Japan). 
The baPWV was measured in patients who had been lying 
in a supine position for at least 5 minutes. Measurements of 
baPWV were repeated twice to confirm reproducibility, and 
the deviation between measurements was within 5%. The 
mean value on the right side was used as the baPWV value 
in each patient.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
635
effects of smoking cessation on central blood pressure
In this study, this measurement was performed by a single 
expert investigator.
Measurement of LVMi and e′
M-mode echocardiography was performed under two-
dimensional echocardiography guidance using a Vivid S6 
ultrasound system (GE Healthcare, Milwaukee, WI) with a 
3-MHz transducer. LVMI was measured by standard M-mode 
echocardiography and determined using the formula reported 
by Devereux et al.12 Longitudinal velocity of the mitral 
annulus was recorded throughout the cardiac cycle at the 
septal annulus in the apical four-chamber view by spectral 
pulsed-wave Doppler imaging.
The peaks of systolic apically directed (s′ velocity) 
and early diastolic (e′ velocity) myocardial velocities were 
measured.
Statistical analysis
Data are shown as means ± SD. Differences between the two 
groups at baseline were analyzed using unpaired t-tests for 
continuous variables and χ2 tests for categorical variables. 
Paired t-tests were used for within-group comparisons, and 
unpaired t-tests were used for between-group comparisons. 
Values of P , 0.05 (two-sided) were considered statistically 
significant. SAS software (v8.2; SAS Institute Inc, Cary, NC) 
was used for all analyses.
Results
No significant difference was observed between the two groups 
in any background variable, including background variables 
known to affect CBP and AI, such as age, renal function, dia-
betes mellitus, dyslipidemia, gender, and BMI (Table 1). About 
30% of the patients had hypertension. No hypotensor was used 
in patients with systolic blood pressure below 150 mmHg.
In the smoking cessation group, the CO level in expired 
gas decreased from 3.8 ± 0.4% to 0.4 ± 0.1% (P , 0.001), 
while that in the smoking group did not change (3.6 ± 0.5% 
before smoking cessation and 3.7 ± 0.5% after smoking ces-
sation, P = 0.65). The change in the CO level in expired gas 
following treatment differed significantly between the two 
groups (P , 0.001).
SBP measured at the brachium showed no significant 
reduction after smoking cessation in either of the two 
groups, and the brachial SBP was not significantly different 
between the two groups. DBP measurement showed results 
similar to those of SBP. In smoking cessation group, the 
SBP was 138.3 ± 6.4 mmHg before smoking cessation and 
136.7 ± 6.4 mmHg after smoking cessation. In the   smoking 
group, the SBP was 135.9 ± 7.3 mmHg before treatment and 
134.8 ± 6.3 mmHg after smoking cessation. No   significant 
difference was observed in DBP and HR between the two 
groups.
CBP, which represents the blood pressure near the origin 
of the aorta, decreased significantly in the smoking cessation 
group from 109.4 ± 2.1 mmHg before smoking cessation to 
102.3 ± 1.7 mmHg after smoking cessation. CBP remained 
unchanged (110.1 ± 2.9 mmHg before smoking cessation and 
111.3 ± 2.8 mmHg after smoking cessation) in the smoking 
group. Thus, the change in CBP after smoking cessation 
  differed significantly between the two groups. Figure 1 shows 
the changes in CBP after smoking cessation from its baseline 
value. The figure shows significant reduction of CBP in the 
smoking cessation group than in the smoking group.
Values for rAIx@75 showed similar trends to those for 
CBP; rAIx@75 (an indicator of arterial stiffness) decreased 
significantly in the smoking cessation group after smok-
ing cessation (77.5 ± 3.4% before smoking cessation and 
71.1 ± 2.4% after smoking cessation). rAIx@75 remained 
unchanged in the smoking group (77.9 ± 3.8% before smok-
ing cessation and 76.9 ± 4.1% after smoking   cessation). The 
change in rAIx@75 following treatment   differed significantly 
Table 1 Baseline characteristics
Smoking  
cessation group 
(n = 37)
Smoking  
group 
(n = 33)
P value
Age (years)   51.3 ± 5.9   53.5 ± 7.9 0.48
Sex (male, %)      69      71 0.72
BMi (kg/m2) 24.5 ± 2.1 23.9 ± 2.5 0.54
SBP (mmHg) 138.3 ± 6.4 135.9 ± 7.3 0.42
DBP (mmHg) 85.4 ± 3.1 84.2 ± 4.6 0.64
cBP (mmHg) 109.4 ± 2.1 110.1 ± 2.9 0.71
HR (bpm) 71.3 ± 5.3 68.4 ± 6.3 0.54
baPWV (cm/s) 1768.3 ± 54.5 1802.5 ± 73.8 0.37
rAix@75 (%) 77.5 ± 3.4 77.9 ± 3.8 0.21
LVMi (g/m2) 113.6 ± 5.5 116.1 ± 3.6 0.16
egFR  
(ml ⋅ min−1 ⋅ 1.73 m−2)
65.3 ± 3.5 67.1 ± 4.8 0.21
HbA1c (%) 5.1 ± 0.3 5.0 ± 0.4 0.51
LDL-c (mg/dL) 105.6 ± 6.3 106.9 ± 8.9 0.55
HDL-c (mg/dL) 48.6 ± 4.8 51.2 ± 5.8 0.16
Tg (mg/dL) 105.8 ± 15.7 110.8 ± 13.8 0.34
UA (mg/dL) 5.4 ± 0.9 5.6 ± 0.6 0.51
e′ (cm/s) 9.5 ± 0.5 9.7 ± 0.7 0.34
Note: Values are means ± standard deviation or n (%). 
Abbreviations: BMi, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; cBP, central blood pressure; HR, heart rate; baPWV, brachial-
ankle pulse wave velocity; rAix@75, normalized augmentation index; LVMi, left 
ventricular  mass  index;  eGFR,  estimated  glomerular  filtration  rate;  LDL-C,  low 
density lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; Tg, 
triglyceride; UA, uric acid; e′, mitral annulus velocity.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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between the two groups. Figure 2 shows the changes in 
rAIx@75 after treatment from its baseline value. rAIx@75 
decreased significantly after smoking cessation in the smok-
ing cessation group than in the smoking group.
Results for baPWV were similar to those of rAIx@75; 
baPWV decreased significantly after smoking cessation in 
the smoking cessation group (1768 ± 54 cm/s before   smoking 
  cessation and 1564 ± 69 cm/s after smoking cessation). 
baPWV remained unchanged (1802 ± 73 cm/s before smoking 
cessation and 1759 ± 85 cm/s after smoking cessation) in the 
smoking group. The change in baPWV after treatment was 
significantly different between the two groups. Figure 3 shows 
the changes in baPWV after treatment from its baseline value. 
baPWV decreased significantly after smoking cessation in the 
smoking cessation group than in the smoking group.
LVMI, an indicator of left ventricular thickening, did 
not decrease significantly after smoking cessation in any of 
the two groups, and there was no significant difference in 
LVMI between the two groups. The LVMI in the smoking 
cessation group was 113.6 ± 5.5 g/m2 before treatment and 
112.9 ± 3.6 g/m2 after smoking cessation and that in the 
  smoking group was 116.1 ± 3.6 g/m2 before smoking cessa-
tion and 115.9 ± 3.3 g/m2 after smoking cessation.
The value of e′, an indicator of left ventricular diastolic 
function, did not decrease significantly after smoking 
  cessation in any of the groups, and there was no significant 
difference in e′ between the two groups. In the smoking 
  cessation group, e′ was 9.5 ± 0.5 cm/s before smoking 
  cessation and 9.4 ± 0.3 cm/s after smoking cessation. In the 
smoking group, e′ was 9.7 ± 0.7 cm/s before smoking 
  cessation and 9.6 ± 0.6 cm/s after smoking cessation.
Adverse events
All patients who entered the randomized phase of the study 
completed the study without experiencing any serious 
adverse events.
Discussion
Minami et al analyzed the relationship between smoking 
habits and AI, brachial blood pressure, and CBP in normal 
men, and reported that brachial blood pressure did not differ 
between smokers and nonsmokers, but CBP and AI were 
higher in smokers than in nonsmokers.3 Our results indicate 
that smoking cessation reduced CBP and AI. We did not 
include smokers with hypertension in our study; thus, it is 
necessary to examine whether smoking cessation reduces 
CBP and AI even in such patients. However, patients with 
hypertension are susceptible to the influence of drug therapy. 
Drugs such as renin angiotensin system inhibitors (angio-
tensin receptor blockers [ARB] and angiotensin-converting 
enzyme inhibitors [ACEI] and calcium channel blockers) are 
known to lower CBP and AI, while those such as diuretics 
and beta-blockers do not lower CBP or AI.4 To avoid such 
influences resulting from drug therapy, we included only 
those patients who did not receive hypotensors.
In the present study, smoking cessation did not affect left 
ventricular thickening or left ventricular diastolic function. 
This may be because reduction of afterload due to decrease in 
CBP and AI did not have a marked impact on left ventricular 
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Figure 2 changes in brachial-ankle pulse wave velocity (baPWV) from baseline to 
week 60.
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Figure 3 changes in normalized augmentation index (rAix@75) from baseline to 
week 60.
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thickening or diastolic function in patients with normal blood 
pressure before smoking cessation.
The question arises of why did smoking cessation lower 
CBP and AI? Some investigators reported that AI is inversely 
correlated with flow-mediated vasodilatation, an indicator 
of endothelial function.19 Thus, the reduction in AI in our 
study may be because of an improvement in endothelial cell 
  function. Mainstream cigarette smoke contains about 4% 
CO, which binds firmly to blood hemoglobin. The CO bound 
to hemoglobin stimulates cholesterol degeneration, which 
results in impairment of the vascular endothelium and stimu-
lation of atherosclerosis.20 The reduced CO level in expired 
gas observed after smoking cessation may be an indicator that 
this treatment decreases the level of hemoglobin-bound CO. 
Tsuchiya et al showed that superoxides are the main reactive 
oxygen species contained in cigarette smoke.21 Smoking 
causes severe accumulation of exogenous active oxygen 
and free radicals, which results in chronic increase in 
oxidative stress,22 possibly leading to vascular endothelial 
dysfunction, vasoconstriction, and vascular inflammation.23 
In our study, smoking cessation probably lowered the chronic 
oxidative stress. These changes might have improved the 
vascular endothelial dysfunction, leading to reduction 
in AI. Nicotine, contained in tobacco smoke, stimulates 
the adrenal gland, causing release of catecholamines and 
stimulation of the sympathetic nervous system and thus 
leading to contraction of peripheral vessels, elevation of 
blood pressure, and an increase in HR.24 In addition, nico-
tine stimulates the release of thromboxane A2, which has 
potent vasoconstrictive activity.25 These factors can lead to 
abnormal vasoconstriction. Smoking cessation had no effect 
on brachial blood pressure, indicating that this system was 
not involved in patients with normal blood pressure. Some 
investigators previously reported a study designed to evalu-
ate the influence of acute and chronic smoking on arterial 
stiffness by analyzing baPWV and cardio-ankle vascular 
index (CAVI).26 Their results showed a significant elevation 
in baPWV after smoking.
Chronic smoking is thought to affect CBP through its 
effects on arterial stiffness and wave reflection.27 The results 
from our study suggest that improvement in baPWV and AI 
delayed the pulse-wave velocity and suppressed the increase 
in wave reflection, resulting in reduction of CBP.
Van den Berkmortel et al8 analyzed the relationship 
between smoking cessation and arterial wall thickness and 
stiffness and reported that even after 2 years of smoking 
cessation, the intima-media thickness did not reduce and no 
improvement was observed in the cross-sectional compliance 
or distensibility coefficient. In our study, we did not estimate 
the cross-sectional compliance and distensibility coefficients 
or the intima-media thickness of either the carotid and right 
common femoral arteries.
A recent study28 compared central systolic blood pressure 
(cSBP) and augmentation index (AIx) using two recently 
introduced devices, the Omron HEM-9000 and the Arterio-
graph, with those of the widely used SphygmoCor. Though 
heart rate is an important determinant of AIx, the heart rate 
adjusted AIx value was not statistically different across the 
three devices.
Some limitations of our study should be discussed. Firstly, 
this was not a double-blind randomized trial, and thus, the 
possibility of a significant bias cannot be excluded.   However, 
all measurements were performed by a single   clinical 
  investigator who was blinded to the treatment   allocation; 
therefore, there was no bias in the measurement and evalu-
ation of   laboratory data. Secondly, the study period was 
relatively short and the sample size was small; longer and 
larger studies are necessary to evaluate the long-term effects 
of smoking. In this study, a matched nonsmoker control 
group (individuals who did not smoke for at least more than 
5 years or never smoked at all) was absent. Therefore, we 
cannot determine the time required for the vascular properties 
(CPB, baPWV , rAIx@75, etc) to return to normal. Thirdly, 
the measurement of CO levels to determine compliance with 
cessation is a weak measure because CO has a short half-life 
and therefore the estimation of cessation is weak.
Conclusion
Elevation in CBP, AI, and baPWV are strong risk factors 
for cardiovascular events.5 The present study revealed that 
smoking cessation can suppress CBP and AI. Thus, our results 
indicate the importance of smoking cessation as a primary 
approach for preventing cardiovascular events.
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